文献速递垂体与肾上腺疾病糖尿病

高胰岛素-正葡萄糖钳夹试验证实非经典型先天性肾上腺皮质增生症患者存在胰岛素抵抗

Hyperinsulinemic-Euglycemic Clamp Strengthens the Insulin Resistance in Nonclassical Congenital Adrenal Hyperplasia.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该横断面研究采用高胰岛素-正葡萄糖钳夹技术评估21-羟化酶缺陷所致非经典型先天性肾上腺皮质增生症(NC-CAH)患者的胰岛素敏感性。31例NC-CAH患者(25女,6男,24±10岁)与对照组相比,钳夹试验中Mffm值更低(31±20 vs 55±23 µmol/min⁻¹/kg⁻¹,P=0.002),且与糖皮质激素治疗时长负相关(r=-0.44,P=0.04)。结论认为NC-CAH患者存在胰岛素抵抗,与长期使用及长效糖皮质激素治疗相关。

要点

  • NC-CAH患者钳夹试验Mffm值显著低于对照组,提示胰岛素抵抗。
  • Mffm值与糖皮质激素治疗时长呈负相关(r=-0.44,P=0.04)。
  • 胰岛素抵抗与糖皮质激素类型相关,与雄激素水平无关。

核心结论

  • 采用高胰岛素-正葡萄糖钳夹这一金标准方法,证实NC-CAH患者存在胰岛素抵抗。
  • 胰岛素抵抗与长期使用及长效糖皮质激素治疗相关,与雄激素水平无关。

研究设计与样本

  • 横断面研究,在大学医院门诊开展。
  • 纳入31例NC-CAH患者(25例女性,6例男性;年龄24±10岁),按基因型分为C/NC和NC/NC亚组,并与对照组比较。
  • 22例患者成功完成高胰岛素-正葡萄糖钳夹试验。

主要发现

  • 诊断时C/NC基因型患者基础和ACTH刺激后17-羟孕酮及雄烯二酮水平高于NC/NC基因型。
  • NC-CAH患者腰臀比更高,脂联素和高密度脂蛋白胆固醇水平更低。
  • 空腹血糖、糖化血红蛋白、HOMA-IR、瘦素、IL-6、TNF-α、CRP及颈动脉内膜中层厚度无显著变化。
  • NC-CAH患者Mffm低于对照组(31±20 vs 55±23 µmol/min⁻¹/kg⁻¹,P=0.002)。
  • Mffm值与糖皮质激素治疗时长呈负相关(r=-0.44,P=0.04)。

关键数值与推荐

  • 所有患者均曾使用糖皮质激素,平均使用时间73个月。
  • 22例成功钳夹患者中,13例仍在接受糖皮质激素治疗(3例醋酸可的松、9例地塞米松、1例泼尼松,氢化可的松等效剂量5.5 mg/m²/天),9例已停药但曾使用(氢化可的松等效剂量5.9 mg/m²/天)。

临床怎么用

  • NC-CAH患者应定期监测糖皮质激素替代治疗及心血管代谢风险。
  • 临床需关注长期及长效糖皮质激素治疗对胰岛素敏感性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Insulin sensitivity evaluation by hyperinsulinemic-euglycemic clamp in nonclassical congenital adrenal hyperplasia (NC-CAH) due to 21-hydroxilase deficiency. DESIGN AND SETTING: Cross-sectional study at university hospital outpatient clinics. PATIENTS AND METHODS: NC-CAH patients (25 females, 6 males; 24 ± 10 years) subdivided into C/NC (compound heterozygous for 1 classical and 1 nonclassical allele) and NC/NC (2 nonclassical alleles) genotypes were compared to controls. RESULTS: At diagnosis, C/NC patients presented higher basal and adrenocorticotropin-stimulated 17-hydroxyprogesterone and androstenedione levels than NC/NC genotype. Patients and controls presented similar weight, body mass index, abdominal circumference, and total fat body mass. NC-CAH patients showed higher waist-to-hip ratio, lower adiponectin and lower high-density lipoprotein cholesterol levels with no changes in fasting plasma glucose, glycated hemoglobin, homeostatic model assessment for insulin resistance, leptin, interleukin 6, tumor necrosis factor alpha, C-reactive protein, and carotid-intima-media thickness. All patients had used glucocorticoid (mean time of 73 months). Among the 22 patients with successful clamp, 13 were still receiving glucocorticoid-3 patients using cortisone acetate, 9 dexamethasone, and 1 prednisone (hydrocortisone equivalent dose of 5.5mg/m²/day), while 9 patients were off glucocorticoid but had previously used (hydrocortisone equivalent dose of 5.9mg/m2/day). The NC-CAH patients presented lower Mffm than controls (31 ± 20 vs 55 ± 23µmol/min-1/kg-1, P = 0.002). The Mffm values were inversely correlated with the duration of glucocorticoid treatment (r = -0.44, P = 0.04). There was association of insulin resistance and glucocorticoid type but not with androgen levels. CONCLUSION: Using the gold standard method, the hyperinsulinemic-euglycemic clamp, insulin resistance was present in NC-CAH patients and related to prolonged use and long-acting glucocorticoid treatment. Glucocorticoid replacement and cardiometabolic risks should be monitored regularly in NC-CAH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Delai A, Gomes PM, Foss-Freitas MC, et al. Hyperinsulinemic-Euglycemic Clamp Strengthens the Insulin Resistance in Nonclassical Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2022. PMID: 34693966. doi:10.1210/clinem/dgab767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。